Aesica adds development capability with new purpose built facility
20 April 2017 | By Aesica Pharmaceuticals
Product life cycle services expanded, including for high potent and controlled drugs...
List view / Grid view
News
Novartis expands development programs for NASH with Allergan clinical partnership
20 April 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist...
GeNeuro initiates Phase 2a study in Australia to treat Type 1 Diabetes
19 April 2017 | By Niamh Marriott, Junior Editor
GeNeuro have started a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes. GNbAC1 is a monoclonal antibody designed to...
Optimise indoor climate conditions with Munters
19 April 2017 | By Munters
Munters, global leaders in energy efficient air treatment, is delighted to be exhibiting on Stand 106 at Making Pharmaceuticals...
Novartis’ lymphoma treatment receives FDA breakthrough therapy designation
19 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies. This is…
Enzyvant receives FDA designation for investigational therapy
19 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted Enzyvant’s RVT-802, an investigational tissue-based therapy for the treatment of complete DiGeorge Syndrome (cDGS), breakthrough therapy designation as well as regenerative medicine advanced therapy (RMAT) designation. Both designations confer special access to the Office of Tissues and Advanced Therapies for development…
Precision Polymer Engineering will be exhibiting at Making Pharmaceuticals
19 April 2017 | By Precision Polymer Engineering
Precision Polymer Engineering will be at Stand 303 at Making Pharmaceuticals (25-26 April, Coventry, UK), offering the benefits of our experience in pharmaceutical sealing to solve problems for critical process applications...
Rigel submits new drug application to FDA for Fostamatinib in Chronic ITP
18 April 2017 | By Niamh Marriott, Junior Editor
Rigel Pharmaceuticals has submitted a new drug application to the US FDA for fostamatinib in patients with immune thrombocytopenia...
Amarantus forms Elto Pharma for CNS disorders and MANF Therapeutics for ophthalmology
18 April 2017 | By Niamh Marriott, Junior Editor
Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).
Study finds genetic basis for drug response in childhood absence epilepsy
13 April 2017 | By Niamh Marriott, Junior Editor
A new childhood absence epilepsy study has identified genes that show individual reactions and could be used as a precision medicine approach...
Best practice guide on leachables risk published
12 April 2017 | By Steve Bremer, Managing Editor
The Biophorum Operations Group BPOG has published a best-practices guide for evaluating leachables risk from single-use systems (SUS)...
FDA approves first drug to treat tardive dyskinesia
12 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. Tardive dyskinesia is a neurological disorder characterised by repetitive involuntary movements, usually of the jaw, lips and tongue, such as…
Lonza to host new webinar: “Justifying a paperless solution – building a compelling business case”
Lonza is hosting a free 60-minute webinar on 25 April 2017 on how to create a compelling business case for the implementation of a paperless QC testing solution.
Therapix signs license with Yissum for cannabinoid nasal drug delivery technology
10 April 2017 | By Niamh Marriott, Junior Editor
Therapix Biosciences has signed a sublicense agreement for Yissum Research Development Company of the Hebrew University nasal drug delivery technology...
Jazz Pharmaceuticals submits FDA application for leukaemia treatment
7 April 2017 | By Niamh Marriott, Junior Editor
Jazz Pharmaceuticals completed a rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Vyxeos...
